This development positions the molecule as a potential breakthrough in the treatment of autoimmune and inflammatory diseases. ATI-2138 exhibits the ability to selectively and potently block ...

Aclaris reports potential of ATI-2138 as a dual inhibitor for inflammatory diseases, with promising preclinical and clinical trial results. Aclaris Therapeutics, Inc. has announced the publication ...